Virtu Financial’s Calidi Biotherapeutics CLDI Stock Holding History

Virtu Financial’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18K	Buy	75,769 +54,526	+257%	+$41K	﹤0.01%	1404
2025 Q4	$25K	Buy	+21,243	New	+$31.3K	﹤0.01%	1386
2025 Q3	–	Sell	-853	Closed	-$2K	–	1541
2025 Q2	$2K	Sell	853 -3,708	-81%	-$18K	﹤0.01%	1362
2025 Q1	$31K	Sell	4,561 -1,560	-25%	-$17.8K	﹤0.01%	1067
2024 Q4	$84K	Buy	+6,121	New	+$115K	﹤0.01%	1059
2024 Q3	–	Sell	-216	Closed	-$5K	–	1442
2024 Q2	$5K	Sell	216 -135	-38%	-$4.31K	﹤0.01%	1180
2024 Q1	$24K	Buy	+351	New	+$35.9K	﹤0.01%	1138
2023 Q2	–	Sell	-253	Closed	-$312K	–	1580
2023 Q1	$312K	Buy	253 +145	+134%	+$178K	0.03%	529
2022 Q4	$131K	Sell	108 -555	-84%	-$665K	0.02%	862
2022 Q3	$784K	Buy	+663	New	+$795K	0.07%	253

Other funds holding CLDI

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCI

RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BAM

Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return

Virtu Financial's CLDI Position: Q1 2026 in Review

Virtu Financial increased its Calidi Biotherapeutics (CLDI) stake by 257% in Q1 2026, buying an estimated $41K and bringing the position to 75,769 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #1404.

Virtu Financial first reported a position in CLDI in Q3 2022 and has held it in 10 quarters since. The position peaked at $784K in Q3 2022. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

Virtu Financial held 75,769 shares of Calidi Biotherapeutics worth $18K as of Q1 2026.
Virtu Financial bought 54,526 Calidi Biotherapeutics shares in Q1 2026, an estimated $41K.
Calidi Biotherapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q1 2026, its #1404 holding.
Virtu Financial first reported a position in Calidi Biotherapeutics in Q3 2022 and has held it in 10 quarters since.
Virtu Financial's Calidi Biotherapeutics position peaked at $784K in Q3 2022.
28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.